Jeisys Medical Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	Veri yok

Son yönetim güncellemeleri

Güncelleme yok

Recent updates

Jeisys Medical Inc. (KOSDAQ:287410) Looks Just Right With A 31% Price Jump

May 25

Is There An Opportunity With Jeisys Medical Inc.'s (KOSDAQ:287410) 46% Undervaluation?

May 21

The Returns On Capital At Jeisys Medical (KOSDAQ:287410) Don't Inspire Confidence

Apr 27

Jeisys Medical Inc. (KOSDAQ:287410) Looks Just Right With A 28% Price Jump

Apr 09

CEO

Jeisys Medical CEO'su yok ya da onlar hakkında elimizde veri yok.

Jeisys Medical Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Recent updates

Syracuse Subco, Inc. completed the acquisition of an additional 8.65% stake in Jeisys Medical Inc. (KOSDAQ:A287410).

Syracuse Subco, Inc completed the acquisition of 17.2% stake in Jeisys Medical Inc. (KOSDAQ:A287410) from Kang Dong-hwan and Lee Myung-hoon for approximately KRW 170 billion.

Syracuse Subco, Inc completed the acquisition of 55.4% stake in Jeisys Medical Inc. (KOSDAQ:A287410).

Investor sentiment improves as stock rises 18%

Syracuse Subco, Inc proposed to acquire an additional 72.7% stake in Jeisys Medical Inc. (KOSDAQ:A287410) for approximately KRW 720 billion.

Syracuse Subco, Inc proposed to acquire an additional 72.7% stake in Jeisys Medical Inc. (KOSDAQ:A287410) for approximately KRW 720 billion.

New major risk - Share price stability

Jeisys Medical Inc. (KOSDAQ:287410) Looks Just Right With A 31% Price Jump

Is There An Opportunity With Jeisys Medical Inc.'s (KOSDAQ:287410) 46% Undervaluation?

Investor sentiment improves as stock rises 15%

Consensus EPS estimates fall by 22%

The Returns On Capital At Jeisys Medical (KOSDAQ:287410) Don't Inspire Confidence

Investor sentiment deteriorates as stock falls 21%

Jeisys Medical Inc. (KOSDAQ:287410) Looks Just Right With A 28% Price Jump

Investor sentiment improves as stock rises 15%

Full year 2023 earnings: EPS misses analyst expectations

Investor sentiment deteriorates as stock falls 17%

Third quarter 2023 earnings released: EPS: ₩104 (vs ₩101 in 3Q 2022)

Price target increased by 8.5% to ₩15,467

Price target increased by 9.6% to ₩15,114

Consensus EPS estimates fall by 11%

Price target increased by 7.7% to ₩13,786

Investor sentiment improves as stock rises 19%

Price target increased by 7.3% to ₩12,000

Jeisys Medical Inc. (KOSDAQ:A287410) announces an Equity Buyback for KRW 10,000 million worth of its shares.

Price target decreased by 23% to ₩9,847

Third quarter 2022 earnings released: EPS: ₩101 (vs ₩89.72 in 3Q 2021)

Price target decreased to ₩12,760

Investor sentiment deteriorated over the past week

Price target increased to ₩16,500

Now 22% undervalued

Investor sentiment improved over the past week

CEO